ArticleFrontiers in cell and developmental biology2026
A novel heterozygous splicing variant in the
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Female reproductive aging is a continuum characterized by the depletion of ovarian follicles, including Early Menopause (EM) and Premature ovarian insufficiency (POI).POI exhibits a strong genetic predisposition. Eukaryotic Translation Initiation Factor 4E nuclear import factor 1 (EIF4ENIF1), a key regulator of gene expression, plays a crucial role in oocyte maturation and follicular development. Accumulating evidence indicates that functional abnormalities in EIF4ENIF1 are closely associated with the onset and progression of POI. Therefore, identifying pathogenic variants in EIF4ENIF1 is of significant importance for elucidating its pathogenic mechanisms in POI and advancing clinical diagnosis. Methods: Whole exome sequencing (WES) was performed on the patients with POI, EM or DOR to identify potential pathogenic genes. Variant validation was conducted using Sanger sequencing in patients and their family members. Multiple bioinformatics tools were employed to analyze EIF4ENIF1 transcripts and the three-dimensional structures of encoded proteins. The findings were further validated using reverse transcription polymerase chain reaction (RT-PCR). Results: Through WES analysis, we identified a novel splice-site variant c.1769-2A>G in EIF4ENIF1 gene in the proband. Sanger sequencing confirmed that the proband's mother, maternal grandmother, and sister also carry this variant. RT-PCR and Sanger sequencing detected exon 11 skipping caused by this splicing variant (p.Ile589fs*18). Protein structure prediction indicated disruption of the C-terminal domain of EIF4ENIF1 protein, leading to significant structural alterations in the truncated protein. Conclusion: This study highlights the significance of EIF4ENIF1 splicing variant in the diagnosis and management of patients with POI or EM. This newly discovered variant was identified for the first time in POI family with incomplete penetrance, providing novel molecular genetic evidence for EIF4ENIF1 variants in POI or EM pathogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.